Acquisition · March 25, 2026 · $6.7 billion
| Acquirer | Merck |
| Target | Terns Pharmaceuticals, Inc. |
| Deal type | Acquisition |
| Deal value | $6.7 billion |
| Price Per Share | $53.00 |
| Premium | 31% |
| Financing | Cash |
| Announced | March 25, 2026 |
| Deal stage | Announced |
| Sector | Healthcare |
| Filing Type | news |
Last updated Mar 25, 2026 · Updated Mar 25, 2026
Terns Pharmaceuticals, Inc. (Target)SEC filings →
| Revenue | $0 |
| Net Income | -$88.9M |
| Total Assets | $363.9M |
Merck (Acquirer)SEC filings →
| Revenue | $65.0B |
| Net Income | $18.3B |
| Total Assets | $136.9B |
Ask any question about this deal. Answers are grounded in live news and deal data.
CVC consortium / Recordati
May 22, 2026 · tender offer
Select Medical Holdings Corporation
Apr 28, 2026 · acquisition
Relativity Acquisition Corp. / Instinct Bio Technical Company Inc.
Mar 25, 2026 · merger
VGTEL, Inc. / 4biddenknowledge Inc.
Mar 24, 2026 · acquisition